Close Menu

Quanterix

While the test is unlikely to be used as a diagnostic for the virus, it could be useful for identifying patients at high risk of developing severe disease.

News items for the in vitro diagnostics industry for the week of August 10, 2020.

The company said that it has priced a public offering of 2,651,108 shares of its common stock at $32 per share.

The company posted Q2 revenues of $13.1 million, down from $13.5 million in Q2 2019 but above the consensus Wall Street estimate of $11.8 million.

The researchers found that levels of the marker, which has also been studied in diseases like MS and Alzheimer's, correlated with severity of traumatic brain injury.

The company posted Q1 revenues of $15.7 million, up from $12.3 million in Q1 2019 and above the consensus Wall Street estimate of $13.3 million.

The company posted Q4 revenues of $15.9 million, up from $10.9 million in Q4 2018, and beat the consensus Wall Street estimate of $14.2 million.

A Korean research team is developing a biosensor that boosted sensitivity by using low-cost fabrication to align high-density carbon nanotubes.

The agreement gives Quanterix an opportunity to explore the clinical utility of its Nf-l marker without having to move its instruments into the clinical space.

The firm reported $14.9 million in revenue, driven by an 80 percent increase in product revenues, beating Wall Street expectations.

Pages